TMPRSS11B and neoplasm: Given our demonstration that TMPRSS11B promotes tumor growth and an immunosuppressive TME, the development of monoclonal antibodies or small molecule inhibitors that target this enzyme at the surface of LUSCs represents an exciting avenue for the development of new therapeutics for this deadly malignancy.